Tickers

1. Composite Trajectory Verdict

Given HCAT's recurring revenue model and focus on operating efficiency, the income statement (revenue growth and margin trajectory) and cash flow statement (operating cash generation) carry the most weight for assessing financial performance.

Composite Trajectory: Mixed

The annual income statement shows revenue growth decelerating to 1.5% in 2025 with expanding gross margin, but GAAP net loss widened sharply due to a $110.2M goodwill impairment. Quarterly revenue declined double-digits in Q2 and first-half 2026, while Q2 net loss was flat year-over-year. Operating cash flow collapsed to near zero in 2025 after turning positive in 2024, and the balance sheet shows significant deleveraging but a 41% asset contraction and 76% cash decline. No single statement shows a clear improving or deteriorating trend across all comparable periods.

2. Red Flags

• Goodwill impairments of $105.4M in FY 2025 and $122.5M in the first six months of 2026, totaling $227.9M, against a December 31, 2025 goodwill balance of $209.1M (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, MD&A).
• Operating cash flow collapsed to $0.7M in 2025 from $14.6M in 2024 despite revenue growth (10-K 2025-12-31, Consolidated Statements of Cash Flows).
• Revenue declined 12.6% in Q2 2026 and 11.8% in the first six months of 2026 year-over-year (10-Q 2026-06-30, MD&A).
• Cash and short-term investments dropped 76% to $95.7M at December 31, 2025 from $392.0M at December 31, 2024 (10-K 2025-12-31, Consolidated Balance Sheets).
• Restructuring costs recurred across multiple periods: $8.8M in 2023, $2.1M in 2024, $9.7M in 2025 (10-K 2025-12-31, Note 11 Restructuring Costs).
• Acquisition-related costs net negative in 2025 (-$2.1M) due to fair value changes, after $10.1M in 2024 (10-K 2025-12-31, Consolidated Statements of Operations).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Annual revenue grew 1.5% to $311.1M in 2025 (10-K 2025-12-31, Consolidated Statements of Operations) with gross margin expanding to 39% from 37% (same). However, GAAP net loss widened to $(178.0M) from $(69.5M) driven by a $110.2M goodwill impairment (same). Quarterly Q2 2026 revenue fell 12.6% to $70.5M vs $80.7M in Q2 2025, while Q2 net loss was nearly flat at $(40.5M) vs $(41.0M) (10-Q 2026-06-30, MD&A). Six-month 2026 revenue fell 11.8% to $141.2M and net loss widened to $(151.6M) from $(64.7M) due to a $122.5M goodwill impairment (same). The GAAP profitability trend is mixed: revenue growth positive but decelerating annually and declining quarterly; gross margin improving; but bottom-line results heavily distorted by large, recurring impairments.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Annual operating cash flow dropped to $0.7M in 2025 from $14.6M in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Capitalized internal-use software increased to $19.8M from $14.3M (same), pushing implied free cash flow negative in 2025 after near break-even in 2024. Investing cash flow swung to a $36.2M inflow in 2025 from a $(22.9M) outflow in 2024 due to short-term investment sales (same). Financing cash flow was $(235.8M) in 2025 versus $151.7M inflow in 2024, driven by $232.3M debt repayment and $5.0M share repurchases (10-K 2025-12-31, MD&A Liquidity). Cash and short-term investments fell to $95.7M at year-end 2025 from $392.0M at year-end 2024 (10-K 2025-12-31, Consolidated Balance Sheets). Quarterly cash flow data for 2026 periods is not provided in the filings.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets contracted 41% to $502.6M at December 31, 2025 from $858.9M at December 31, 2024 (10-K 2025-12-31, Consolidated Balance Sheets), primarily due to the $105.4M goodwill impairment (10-K 2025-12-31, Consolidated Statements of Operations) and a $198.8M net cash decrease (10-K 2025-12-31, Consolidated Statements of Cash Flows). Goodwill fell to $209.1M from $259.8M (10-K 2025-12-31, Consolidated Balance Sheets). Long-term debt (net carrying) reduced to $153.3M from $382.4M after repaying the $230M convertible notes (10-K 2025-12-31, Note 10 Debt). Stockholders' equity declined to $245.8M from $365.2M (same). The current ratio improved to 1.89x (current assets $169.3M vs current liabilities $89.6M) from 1.43x (current assets $465.7M vs current liabilities $325.9M) (same). The balance sheet shows deleveraging but a significantly smaller asset base and reduced liquidity.

6. Data Gaps

• Quarterly cash flow statements for Q1 2026, Q2 2026, Q3 2025, and Q4 2025.
• Detailed quarterly income statements for Q1 2026, Q3 2025, and Q4 2025.
• Segment revenue and profitability for quarterly periods in 2026.
• Full 10-Q financial statements for periods ended March 31, 2026, September 30, 2025, and June 30, 2025 (only MD&A highlights provided for Q2 2026).